What Alvimedica does

Alvimedica is a privately held global manufacturer of interventional medical devices headquartered in Istanbul, Turkey, founded in 2007. The company designs, manufactures, and commercializes drug-eluting stents (DES), balloon catheters, and diagnostic and guiding catheters used by interventional cardiologists and vascular surgeons. Its commercial operations span 7 countries across Europe and Asia Pacific via wholly-owned subsidiaries, with R&D and manufacturing concentrated in Italy (via CID S.p.A., a group member in Saluggia) and Turkey.

The company's core technology centers on a proprietary polymer-free drug-eluting platform built around two differentiated technical components: the Amphilimus formulation, a Sirolimus + Fatty Acid combination designed to enhance drug absorption in vascular smooth muscle cells, and the Abluminal Reservoir Technology (ART), which is described as the only polymer-free technology enabling precise outward (abluminal) drug elution control. The product portfolio comprises four main SKUs: Cre8 (polymer-free coronary DES), Cre8 EVO (enhanced second-generation coronary DES), Cre8 BTK (polymer-free DES for below-the-knee peripheral interventions), and the Alvision KAPLAN radial diagnostic catheter portfolio. Cre8 EVO's clinical positioning is supported by the SUGAR randomized controlled trial, where it demonstrated superior target lesion failure outcomes versus Onyx DES in diabetic patients (7.2% vs 10.9%, p=0.030) — an important given the well-documented poorer PCI outcomes in diabetic populations.

Alvimedica operates a direct B2B sales-led commercial model, selling its devices through its own commercial subsidiaries directly to hospitals and cath labs. The company does not disclose pricing, and revenue figures are not publicly available. Marketing reach to healthcare professionals is executed through the company website, an e-learning platform (Alvimedica Academy), and clinical evidence dissemination. No public funding rounds, institutional investors, or acquisition history are disclosed in the available data.

Name

Alvimedica

Legal name

ALVIMEDICA TIBBI URUNLER SAN. VE DIS TICARET A.S.

Website

https://alvimedica.com

Company type

Private

Founded year

2007

Operating status

Operating

Headcount range

101–250 employees

Short description

Alvimedica is a privately held Turkish-anchored medical device manufacturer specializing in polymer-free drug-eluting stents and interventional cardiology catheters, selling directly to hospitals and cath labs across 7 countries in Europe and Asia Pacific, with manufacturing in Turkey and Italy via its CID S.p.A. subsidiary.

Ownership category

akta.pro rank

Product category

Interventional Cardiology Devices

NAICS

Surgical Appliance and Supplies Manufacturing (339113), Surgical and Medical Instrument Manufacturing (339112)

SIC

Surgical & Medical Instruments & Apparatus (3841)

akta.pro primary industry

Coronary Stents & Drug-Eluting Technologies (HLAHAFAA)

Keywords

• Drug-eluting stents
• Interventional cardiology devices
• Coronary stents
• Peripheral vascular stents
• Diagnostic catheters

Headquarters

HQ city

Çatalca

Offices8 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Supply Chain, Personnel, Operations, Technology or R&D, Marketing or Sales

Revenue model

1. Interventional Cardiology Devices: Alvimedica generates revenue from the manufacture and sale of proprietary drug-eluting stents (DES) and related interventional cardiology products including Cre8, Cre8 EVO, and the Alvision KAPLAN diagnostic catheter portfolio. The company sells globally through its own commercial subsidiaries across 7+ countries.
2. Endovascular Devices: Revenue from peripheral vascular devices including the Cre8 BTK polymer-free stent for below-the-knee interventions.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels3 records

Core offering

Alvimedica manufactures and globally sells interventional cardiology and endovascular medical devices, with a primary focus on polymer-free drug-eluting stents (the Cre8™, Cre8™ EVO, and Cre8™ BTK platforms) and a radial-access diagnostic catheter portfolio (Alvision™ KAPLAN curves). Devices are produced in Italy (CID S.p.A.) and sold directly to hospitals, cath labs, and interventional cardiology professionals across more than seven countries through wholly-owned commercial subsidiaries.

Product overview

Alvimedica is a global manufacturer of interventional medical devices specializing in drug-eluting stents (DES) and endovascular products. The product portfolio centers on three main DES platforms: Cre8™ (polymer-free with Amphilimus™ formulation combining Sirolimus with Fatty Acid), Cre8™EVO (enhanced second-generation version), and Cre8™ BTK (below-the-knee peripheral application). Additionally, the company offers the Alvision™ KAPLAN curves radial portfolio for diagnostic procedures. All Cre8™ devices feature abluminal reservoir technology enabling polymer-free drug elution. The company focuses on tackling complex clinical conditions including cardiovascular disease and diabetes, with Cre8™ EVO demonstrating superior clinical outcomes compared to competitors in diabetes mellitus patients based on independent SUGAR RCT data.

Differentiator

Problem solved

Functional benefit

Products and services

• DES – Cre8™ Polymer-free Amphilimus™ (Sirolimus + Fatty acid) eluting coronary stent for interventional cardiology procedures performed in hospitals and cath labs.
• DES – Cre8™ EVO Enhanced polymer-free drug-eluting stent with the improved Amphilimus™ formulation, designed for superior efficacy particularly in diabetes mellitus patients undergoing PCI.
• DES B.E. – Cre8™ BTK Polymer-free Amphilimus™ (Sirolimus + Fatty Acid) eluting stent designed for below-the-knee (BTK) peripheral interventions; absence of polymer minimizes inflammation and thrombosis risk while the proprietary formulation enhances drug absorption.
• Alvision™ KAPLAN curves radial portfolio Radial access diagnostic catheter portfolio featuring specialized curve configurations, intended for diagnostic procedures performed via the radial approach in interventional cardiology.

Named customers1 record

Segments2 records

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Scale indicators1 record

Recent moves4 records

Expansion highlights4 records

Direct peers

• Biotronik: Biotronik is a German privately-held medical device company whose Orsiro sirolimus-eluting stent is the most prominent polymer-free (with bioabsorbable polymer coating) DES competitor. Both companies operate at similar scale (~1B-2B employees range), focus on polymer-free DES differentiation, and run direct sales into hospitals globally. Most direct comparable peer for Alvimedica's core product strategy.
• Lepu Medical: Lepu's Partner and Nano+ sirolimus-eluting stents are widely distributed coronary DES products targeting China, emerging Asia, and select EMEA markets. Comparable mid-sized international interventional cardiology manufacturer with broad emerging-market presence.
• MicroPort Scientific: MicroPort Scientific's Firehawk and Firebird DES compete in coronary DES alongside Alvimedica's Cre8 line. Publicly listed with global commercial operations spanning China, Europe, and emerging Asia, MicroPort represents the closest at-scale publicly traded DES challenger similar in international profile to Alvimedica.
• Terumo: Terumo's Ultimaster (sirolimus-eluting) DES competes within the same coronary interventional cardiology category as Alvimedica's Cre8 platform. Both companies are mid-sized, internationally diversified manufacturers of interventional devices with their own direct sales models. Closest Japanese APAC comparable peer.
• Translumina Therapeutics: Translumina's Yukon Choice PC and TAZZA sirolimus-eluting stents compete in the same Indian and emerging-market DES segment as Alvimedica's Cre8 line. India-based mid-sized manufacturer with international distribution; comparable scale and pricing-tier positioning.
• Sahajanand Medical Technologies: SMT's Supraflex and Supraflex Cruz sirolimus-eluting stents are direct competitors to Alvimedica's Cre8 family, particularly in emerging-market tender business. Indian-headquartered with growing European and emerging Asia presence, SMT is comparable in scale, regional commercial model, and product positioning.

Broad incumbents

• Abbott Laboratories: Abbott's Xience (everolimus-eluting) DES family remains the global DES market share leader with deep clinical evidence and broad hospital penetration. As the largest single DES franchise, Abbott's commercial reach and clinical evidence base set the benchmark Alvimedica must differentiate against.
• Medtronic: Medtronic's Onyx (zotarolimus-eluting) and Resolute DES are direct competitors to Cre8 EVO and the comparator arm in the SUGAR RCT. As the largest interventional cardiology franchise by revenue globally, Medtronic sets product, evidence, and pricing standards against which Alvimedica must compete. Most relevant broad incumbent.
• Boston Scientific: Boston Scientific's SYNERGY (everolimus-eluting bioabsorbable polymer-coated) and Promus DES compete head-to-head with Cre8 EVO in coronary indications. As a top-3 global interventional cardiology incumbent with broad structural heart, peripheral, and CRM franchises, Boston Scientific shapes hospital-level formulary decisions Alvimedica must navigate.

Emerging players

• InspireMD: InspireMD's CGuard carotid and MeshGuard/MGuard coronary platforms are niche interventional cardiology/devices targeting specific indications. Significantly smaller in scale and with a narrower product portfolio than Alvimedica, but competes in adjacent coronary and peripheral stent categories with their mesh-covered stent technology.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks5 records

Key highlights6 records

Customer concentration

• Xx.com/alvimedica
• Facebookfacebook.com/Alvimedica
• LinkedInlinkedin.com/company/alvimedica

Revenue estimate

Valuation estimate

Number of profiles

Subsidiaries6 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Alvimedica